美诺华子公司获得厄贝沙坦氢氯噻嗪片药品注册证书

Core Viewpoint - Meinuo Pharma (603538.SH) has received approval from the National Medical Products Administration for its product, Irbesartan Hydrochlorothiazide Tablets, which is indicated for the treatment of primary hypertension [1] Group 1: Product Approval - Meinuo Pharma's wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Irbesartan Hydrochlorothiazide Tablets from the National Medical Products Administration [1] - The combination of Irbesartan, an angiotensin II receptor antagonist, and Hydrochlorothiazide, a thiazide diuretic, is designed to provide a synergistic effect in lowering blood pressure within the recommended therapeutic dosage range [1]